Literature DB >> 12624790

Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases.

Christian Mawrin1, Anna Brunn, Christoph Röcken, J Michael Schröder.   

Abstract

Matrix metalloproteinases (MMPs) are endoproteases that have been implicated in the pathogenesis of inflammatory and vasculitic neuropathies. In systemic lupus erythematosus (SLE), a peripheral neuropathy is frequently seen that is thought to be caused by ischemic nerve damage due to vasculopathy and/or vasculitis of the nutritional vessels. However, the exact pathomechanisms causing SLE neuropathy are largely unknown. Elevated MMP levels have been reported in the serum of SLE patients. Supposing that altered expression of MMPs may contribute to vessel wall damage in SLE neuropathy, we investigated the expression of MMP-1, -2, -3, -9, -10 and -13, and their tissue inhibitors (TIMP-1 and -2) in sural nerves from 12 SLE patients in comparison to normal controls. All MMPs could be detected within blood vessel walls from SLE nerves, whereas in controls MMP-3 and MMP-9 was not found. TIMP-1 and TIMP-2, on the other hand, were not informative. Generally, small and large nutritional vessels in the epineurium were immunoreactive for MMPs and TIMPs. Mononuclear cells, which expressed MMP-1, - 3, -10, -13, and TIMP-1 were also observed in most of the SLE nerves, mostly around epineurial blood vessels, but only occasionally in controls. This indicates that expression of MMPs in mononuclear cells may be related to leukocyte trafficking through the vessel walls. However, the density of TIMP-positive and MMP-positive inflammatory cells did not correlate with morphometric parameters regarding the severity of the neuropathy. Our findings suggest that especially the up-regulation of MMP-3 and MMP-9 within the vessel walls may be responsible for the vascular damage seen in SLE and the resulting chronic combined axonal and demyelinating type of neuropathy frequently found in SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12624790     DOI: 10.1007/s00401-002-0653-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  13 in total

Review 1.  Clinical utility of peripheral nerve biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

2.  TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve.

Authors:  Veronica I Shubayev; Mila Angert; Jennifer Dolkas; W Marie Campana; Kai Palenscar; Robert R Myers
Journal:  Mol Cell Neurosci       Date:  2005-11-16       Impact factor: 4.314

3.  Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve.

Authors:  Sharmila Chattopadhyay; Robert R Myers; Julie Janes; Veronica Shubayev
Journal:  Brain Behav Immun       Date:  2006-12-26       Impact factor: 7.217

4.  Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells.

Authors:  Sonya J Wolf; Shannon N Estadt; Jonathan Theros; Tyson Moore; Jason Ellis; Jianhua Liu; Tamra J Reed; Chaim O Jacob; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Autoimmun       Date:  2019-06-24       Impact factor: 7.094

5.  MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.

Authors:  Hideo Kobayashi; Sharmila Chattopadhyay; Kinshi Kato; Jennifer Dolkas; Shin-Ichi Kikuchi; Robert R Myers; Veronica I Shubayev
Journal:  Mol Cell Neurosci       Date:  2008-09-05       Impact factor: 4.314

6.  Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis.

Authors:  Zhongxin Jiang; Tao Sui; Bin Wang
Journal:  Rheumatol Int       Date:  2009-09-25       Impact factor: 2.631

7.  Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview.

Authors:  Elias Toubi; Aharon Kessel; Ellen Bamberger; Theo Dov Golan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-04

8.  Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets.

Authors:  Shaheen E Lakhan; Mihaela Avramut
Journal:  Pain Res Treat       Date:  2012-08-28

9.  Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.

Authors:  Ewa Robak; Agnieszka Wierzbowska; Magdalena Chmiela; Liliana Kulczycka; Anna Sysa-Jedrejowska; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

10.  Peripheral neuropathies due to systemic lupus erythematosus in China.

Authors:  Wang Xianbin; Wang Mingyu; Xu Dong; Li Huiying; Xu Yan; Zhang Fengchun; Zeng Xiaofeng
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.